Feby Abraham, Ph.D.
Executive Vice President, Chief Strategy and Innovations Officer
Memorial Hermann Health System
Feby is the EVP, Chief Strategy and Innovations Officer at Memorial Hermann Health System. In this role, he is responsible for
1. Strategy -- develop strategic priorities, drive annual strategic planning for executing the strategy in close collaboration with operational and functional leaders
2. Corporate development efforts (joint ventures, strategic partnerships & alliances, M&A) that bring best-in-class capabilities with leading partners. Examples include GoHealth (urgent care), Accentcare (home health & hospice), Helix (population genomics), Contessa (hospital-at-home), Hamilton health box (on-site clinics), PaRC (divestment of residential behavioral health)
3. Strategic direct equity investing efforts focused on supporting the growth of differentiated & innovative companies that are transforming the way healthcare is delivered & accessed. Examples include AdaptX, CapitalRx, Cedar, Clarify, Enablecomp, Foodsmart, Hazel, Kabafusion, Laudio, Leiters, Monogram, Saferide, Spendmend, Truveta, Wellvana, Xealth
4. Co-sponsoring innovation hub efforts bringing in novel solutions to solve pain points & unmet needs across clinical, administrative and operational workflows.
5. Roadmap for the system’s transition to value efforts including expanding risk-bearing businesses (e.g., health plan)
6. Strategic market insights (data driven granular industry trends & implications)
Prior to this role, Feby was a partner at McKinsey (~12 years) where he
1. Advised private equity clients and their portfolio companies across deal cycle – development of investment themes, due-diligence (advised in >250 asset evaluations), full potential planning, portfolio value creation (margin improvement, revenue growth, inorganic theses, etc.), exit strategy
2. Advised companies in the building products value chain ( manufacturers, distributors) on strategy, M&A and integration (he advised several of the large consolidation events in the industry between 2015-2020), commercial and operational performance improvement, accelerating digital transformation in the industry
3. Advised companies in the healthcare value chain – biopharma & medical products, several healthcare services companies looked at by private equity firms